Artivion, Inc. (NYSE:AORT) VP Andrew M. Green Sells 7,618 Shares

Artivion, Inc. (NYSE:AORT) VP Andrew M. Green sold 7,618 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $30.00, for a total value of $228,540.00. Following the completion of the sale, the vice president now directly owns 33,503 shares in the company, valued at $1,005,090. The trade was a 18.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Artivion Stock Down 0.2 %

NYSE AORT traded down $0.06 during mid-day trading on Wednesday, reaching $29.62. The stock had a trading volume of 167,598 shares, compared to its average volume of 224,405. Artivion, Inc. has a 1 year low of $16.48 and a 1 year high of $30.10. The stock has a market cap of $1.24 billion, a PE ratio of -1,484.00 and a beta of 1.75. The company has a fifty day moving average price of $27.17 and a 200 day moving average price of $25.91. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33.

Hedge Funds Weigh In On Artivion

A number of hedge funds have recently added to or reduced their stakes in AORT. Perceptive Advisors LLC raised its stake in Artivion by 4.7% during the 2nd quarter. Perceptive Advisors LLC now owns 2,793,703 shares of the company’s stock valued at $71,658,000 after buying an additional 124,725 shares during the last quarter. Vanguard Group Inc. raised its stake in Artivion by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company’s stock valued at $56,388,000 after buying an additional 33,982 shares during the last quarter. Wellington Management Group LLP raised its stake in Artivion by 2.9% during the 3rd quarter. Wellington Management Group LLP now owns 1,656,264 shares of the company’s stock valued at $44,090,000 after buying an additional 46,267 shares during the last quarter. First Eagle Investment Management LLC raised its stake in Artivion by 4.9% during the 2nd quarter. First Eagle Investment Management LLC now owns 598,148 shares of the company’s stock valued at $15,342,000 after buying an additional 27,906 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Artivion by 58.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock valued at $9,074,000 after acquiring an additional 125,668 shares during the period. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 price objective on shares of Artivion in a research report on Friday, September 27th. Oppenheimer lifted their price objective on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. Stifel Nicolaus lifted their target price on shares of Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a report on Friday, September 13th. Finally, JMP Securities started coverage on shares of Artivion in a report on Wednesday, October 23rd. They set an “outperform” rating and a $33.00 target price for the company. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $31.00.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.